Eric Lefkofsky is one of Chicago’s most influential persons. He has founded and co-founded many important organizations which continue to impact society in various ways. His most conspicuous position at the moment though is Chief Executive Officer of Tempus Lab; a Tech outfit he founded. He has invested most of his energies and resources in disruptive technologies. Tempus Lab has drawn a lot of attention because it is directed at trying to solve the cancer menace. It is an operating system that uses analytics to resolve cancer mysteries. Mr. Eric Lefkofsky is also the co-founder of Lightbank, chairman and co-founder GRPN as listed on NASDAQ, Mediaocean, among other key technology hubs. Mr. Lefkofsly also gives back to society. He and his wife started the Lefkofsky Foundation for charity purposes. Lefkofsky is a Trustee of Lurie Children’s Hospital, Chicago. He holds a JD from the University of Michigan.
Tempus Labs Background Summary
Tempus Labs, an initiative by Lefkofski that started barely three years ago but has already hit the headlines in Chicago and around the globe has given new hope to the world of cancer treatment. Tempus Labs is a tech operating system that Lefkofski uses to analyze cancer patient data for a variety of medical uses. It has been rated as one of the best ten technology startups in the health sector. Tempus Labs collaborates with nearly all cancer centers across the USA. Tempus Labs offers services ranging from holistic cancer testing, cancer patient tumor sequencing, RNA tumor sequencing, cultures of tumor cells, drug testing, establishing a database for all the layers of information from the tests, medical imaging a lots more. Tempus Labs presents a whole new way of battling cancer; from testing to possible therapies.
Cutting Edge Cancer Treatment
Tempus Labs has made a mark in the cancer testing procedures. It has been noted as one of the three most important technological inventions in the health sector. The other two include gene editing and gene therapy. The two have made it possible to treat ailments that were believed not to have treatment. Tempus Labs has already attracted funding to the tune of $130 million. It is valued at about 700 million US dollars. Tempus Labs provides a platform for machine learning. It is the first personalized cancer treatment facilitating technology on the market. It’s inbuilt precision technologies including DNA and RNA sequencing, and data analysis helps physicians to make fast decisions regarding the course of action for a specific cancer case.
To Read More Clock Here